HALO logo

Halozyme Therapeutics (HALO)

Profile

Full Name

Halozyme Therapeutics, Inc.

Ticker Symbol

HALO

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

March 16, 2004

Indexes

Not included

Website

http://halozyme.com

Employees

350

Key Details

Price

$60.49(+2.09%)

Market cap

$7.45B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$1.02B(+22.44% YoY)

Annual EPS

$3.43(+63.33% YoY)

PE ratio

17.64

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$60.49
HALO price is $60.49

30-Day Relative Volume

0.59
HALO 30-day relative volume is 0.59

Price Performance

Price Most recent change

+2.09%
HALO price was up +2.09% on Apr 25, 2025

Price YTD change

+26.52%
HALO price is up +26.52% since January 1st

Price 1-year change

+57.28%
HALO price is up +57.28% year-on-year

Price 3-year change

+35.6%
HALO price is up +35.6% over the past 3 years

Price Range

Price All-time high

$66.00
HALO price is currently -8.35% below its historical high of $66.00

Price 3-year low

$29.85
HALO price is currently +102.65% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$7.45B
HALO market capitalization is $7.45 billion

Market cap 3-year change

+21.11%
HALO market capitalization is up +21.11% over the past 3 years

Market cap All-time high

$8.23B
HALO market capitalization is currently -9.53% below its historical high of $8.23 billion

Market cap sector rank

91.22%
HALO market capitalization is higher than 91.22% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-3.17%
HALO shares outstanding is down -3.17% year-on-year

Shares Outstanding 3-Year Change

-10.69%
HALO shares outstanding is down -10.69% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.71
HALO beta is 0.71

200-day SMA

$56.00
HALO price is currently +8.02% above its 200-day simple moving average

50-day SMA

$60.46
HALO price is currently +0.05% above its 50-day simple moving average

RSI

51.33
HALO 14-day relative strength index is 51.33

Volume

0.59
HALO 30-day relative volume is 0.59

ATR

$2.31
HALO average true range is $2.31

10-day Historical Volatility

38.20%
HALO 10-day historical volatility is 38.20%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$1.02B
HALO annual revenue is $1.02 billion

Revenue Analysts estimate

$1.19B
HALO annual revenue is currently -14.76% lower than the consensus analysts' forecast

Revenue 1-year change

+22.44%
HALO annual revenue is up +22.44% year-on-year

Revenue Sector rank

80.09%
HALO annual revenue is higher than 80.09% of companies in Healthcare sector

EPS

EPS

$3.43
HALO annual earnings per share is $3.43

EPS Analysts estimate

$5.00
HALO annual earnings per share is currently -31.43% lower than the consensus analysts' forecast

EPS 1-year change

+63.33%
HALO annual earnings per share is up +63.33% year-on-year

EPS Sector rank

94.41%
HALO annual earnings per share is higher than 94.41% of companies in Healthcare sector

Profit

Gross profit

$855.91M
HALO annual gross profit is $855.91 million

Gross margin

84.30%
HALO annual gross profit margin is 84.30%

Operating profit

$551.48M
HALO annual operating income is $551.48 million

Operating margin

54.32%
HALO annual operating profit margin is 54.32%

Net income

$444.09M
HALO annual net profit is $444.09 million

Net margin

43.74%
HALO annual net profit margin is 43.74%

Expenses

Total expenses

$463.85M
HALO annual total expenses is $463.85 million

Operating expenses

$304.43M
HALO annual total operating expenses is $304.43 million

Cost of goods sold

$159.42M
HALO annual cost of goods sold is $159.42 million

Selling, general & administrative expenses

$154.34M
HALO annual SGA is $154.34 million

Depreciation and amortization

$81.31M
HALO annual depreciation & amortization is $81.31 million

Interest expense

$18.09M
HALO annual interest expense is $18.09 million

Income tax

$113.04M
HALO annual income tax is $113.04 million

EBIT & EBITDA

EBIT

$575.23M
HALO annual earnings before interest & taxes is $575.23 million

EBITDA

$656.54M
HALO annual EBITDA is $656.54 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$2.06B
HALO annual total assets is $2.06 billion

Non current assets

$978.14M
HALO annual long term assets is $978.14 million

Current assets

$1.09B
HALO annual total current assets is $1.09 billion

Cash and cash equivalents

$115.85M
HALO annual cash & cash equivalents is $115.85 million

Accounts receivable

$296.94M
HALO annual accounts receivable is $296.94 million

Inventory

$141.86M
HALO annual inventory is $141.86 million

Liabilities

Total liabilities

$1.70B
HALO annual total liabilities is $1.70 billion

Long term liabilities

$1.56B
HALO annual total long term liabilities is $1.56 billion

Current liabilities

$139.10M
HALO annual total current liabilities is $139.10 million

Accounts payable

$10.25M
HALO annual accounts payable is $10.25 million

Debt

Total debt

$1.51B
HALO annual total debt is $1.51 billion

Total debt 1-year change

+0.44%
HALO annual total debt is up +0.44% year-on-year

Long term debt

$1.51B
HALO annual long term debt is $1.51 billion

Short term debt

-
HALO annual short term debt value is unknown

Equity & Capital

Shareholders equity

$363.82M
HALO annual stockholders equity is $363.82 million

Book value

$363.82M
HALO annual book value is $363.82 million

Retained earnings

$359.87M
HALO annual retained earnings is $359.87 million

Working capital

$946.24M
HALO annual working capital is $946.24 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$479.06M
HALO annual cash flow from operations is $479.06 million

Cash from operations 1-year change

+23.29%
HALO annual cash flow from operations is up +23.29% year-on-year

Cash from investing

-$262.72M
HALO annual cash flow from investing activities is -$262.72 million

Cash from investing 1-year change

-171.1%
HALO annual cash flow from investing activities is down -171.1% year-on-year

Cash from financing

-$218.86M
HALO annual cash flow from financing activities is -$218.86 million

Cash from financing 1-year change

+46.36%
HALO annual cash flow from financing activities is up +46.36% year-on-year

CAPEX

CAPEX

$10.70M
HALO annual capital expenditures is $10.70 million

CAPEX 1-year change

-30.06%
HALO annual capital expenditures is down -30.06% year-on-year

Free Cash Flow

Free cash flow

$468.37M
HALO annual free cash flow is $468.37 million

Free cash flow 1-year change

+25.47%
HALO annual free cash flow is up +25.47% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

84.30%
HALO annual gross profit margin is 84.30%

Operating margin

54.32%
HALO annual operating profit margin is 54.32%

Net margin

43.74%
HALO annual net profit margin is 43.74%

ROA & ROE

ROA

23.39%
HALO annual return on assets is 23.39%

ROE

198.42%
HALO annual return on equity is 198.42%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

17.64
HALO price to earnings ratio is 17.64

PE ratio Sector rank

32.35%
HALO price to earnings ratio is higher than 32.35% of companies in Healthcare sector

PB Ratio

PB ratio

20.48
HALO price to book ratio is 20.48

PB ratio Sector rank

96.68%
HALO price to book ratio is higher than 96.68% of companies in Healthcare sector

PS Ratio

PS ratio

7.34
HALO price to sales ratio is 7.34

PS ratio Sector rank

72.99%
HALO price to sales ratio is higher than 72.99% of companies in Healthcare sector

Enterprise value

Enterprise value

$8.84B
HALO enterprise value is $8.84 billion

Enterprise value Sector rank

91.49%
HALO enterprise value is higher than 91.49% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

13.46
HALO EV/EBITDA is 13.46

EV/EBITDA Sector rank

86.19%
HALO EV/EBITDA is higher than 86.19% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

7.80
HALO annual current ratio is 7.80

Quick ratio

6.78
HALO annual quick ratio is 6.78

Leverage

Debt to equity

4.14
HALO annual debt to equity ratio is 4.14

Interest coverage ratio

31.79
HALO annual interest coverage ratio is 31.79

Risk & Stability

Piotroski F-Score

8
HALO piotroski f-score is 8

Altman Z-Score

4.84
HALO altman z-score is 4.84

Analyst ratings

Recent major analysts updates

Apr 21, 25 JP Morgan
Neutral
Mar 6, 25 HC Wainwright & Co.
Buy
Feb 20, 25 Benchmark
Buy
Feb 19, 25 HC Wainwright & Co.
Buy
Feb 4, 25 HC Wainwright & Co.
Buy
Jan 13, 25 Wells Fargo
Equal-Weight
Jan 10, 25 Piper Sandler
Neutral
Jan 10, 25 HC Wainwright & Co.
Buy
Dec 30, 24 HC Wainwright & Co.
Buy
Dec 18, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

HQY logo
HealthEquity (HQY)
CORT logo
Corcept Therapeutics Incorporated (CORT)
ENSG logo
Ensign (ENSG)
MDGL logo
Madrigal Pharmaceuticals (MDGL)
RVMD logo
Revolution Medicines (RVMD)
ROIV logo
Roivant Sciences (ROIV)
LNTH logo
Lantheus Holdings (LNTH)
TECH logo
Bio-Techne (TECH)
BBIO logo
BridgeBio Pharma (BBIO)
  • What is the ticker symbol for Halozyme Therapeutics?
  • Does Halozyme Therapeutics pay dividends?
  • What sector is Halozyme Therapeutics in?
  • What industry is Halozyme Therapeutics in?
  • What country is Halozyme Therapeutics based in?
  • When did Halozyme Therapeutics go public?
  • Is Halozyme Therapeutics in the S&P 500?
  • Is Halozyme Therapeutics in the NASDAQ 100?
  • Is Halozyme Therapeutics in the Dow Jones?
  • When was Halozyme Therapeutics's last earnings report?
  • When does Halozyme Therapeutics report earnings?
  • Should I buy Halozyme Therapeutics stock now?

What is the ticker symbol for Halozyme Therapeutics?

The ticker symbol for Halozyme Therapeutics is NASDAQ:HALO

Does Halozyme Therapeutics pay dividends?

No, Halozyme Therapeutics does not pay dividends

What sector is Halozyme Therapeutics in?

Halozyme Therapeutics is in the Healthcare sector

What industry is Halozyme Therapeutics in?

Halozyme Therapeutics is in the Biotechnology industry

What country is Halozyme Therapeutics based in?

Halozyme Therapeutics is headquartered in United States

When did Halozyme Therapeutics go public?

Halozyme Therapeutics's initial public offering (IPO) was on March 16, 2004

Is Halozyme Therapeutics in the S&P 500?

No, Halozyme Therapeutics is not included in the S&P 500 index

Is Halozyme Therapeutics in the NASDAQ 100?

No, Halozyme Therapeutics is not included in the NASDAQ 100 index

Is Halozyme Therapeutics in the Dow Jones?

No, Halozyme Therapeutics is not included in the Dow Jones index

When was Halozyme Therapeutics's last earnings report?

Halozyme Therapeutics's most recent earnings report was on Feb 18, 2025

When does Halozyme Therapeutics report earnings?

The next expected earnings date for Halozyme Therapeutics is May 7, 2025

Should I buy Halozyme Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page